Clinical Study of Abiraterone Acetate and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

This study is ongoing, but not recruiting participants.

Study NCT00485303 Information provided by Cougar Biotechnology, Inc.

First Received: June 8, 2007 Last Updated: February 15, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	June 2011
Estimated Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

No publications provided by Cougar Biotechnology, Inc.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol. 2011 Nov;60(5):897-904. Epub 2011 Jul 14.